CA3014071C - Methodes pour l'utilisation de 5'-adenosine diphosphate ribose (adpr) - Google Patents

Methodes pour l'utilisation de 5'-adenosine diphosphate ribose (adpr)

Info

Publication number
CA3014071C
CA3014071C CA3014071A CA3014071A CA3014071C CA 3014071 C CA3014071 C CA 3014071C CA 3014071 A CA3014071 A CA 3014071A CA 3014071 A CA3014071 A CA 3014071A CA 3014071 C CA3014071 C CA 3014071C
Authority
CA
Canada
Prior art keywords
adpr
patient
isotopologue
tautomer
stereoisomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3014071A
Other languages
English (en)
Other versions
CA3014071A1 (fr
Inventor
Robert Shalwitz
Original Assignee
Invirsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invirsa Inc filed Critical Invirsa Inc
Priority claimed from PCT/US2017/018253 external-priority patent/WO2017143113A1/fr
Publication of CA3014071A1 publication Critical patent/CA3014071A1/fr
Application granted granted Critical
Publication of CA3014071C publication Critical patent/CA3014071C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

Il est décrit des méthodes pour l’utilisation de 5’-adénosine diphosphate ribose de la formule (lisez la formule ci-dessus), et des compositions de celui-ci, pour traiter, gérer, ou prévenir des maladies ou états pathologiques associés à un adénovirus, des troubles oculaires, le cancer ou des maladies ou états pathologiques provoqués par une infection, l’inflammation, des lésions physiques, chimiques ou thermiques, ou des lésions causées par un rayonnement.
CA3014071A 2016-02-18 2017-02-17 Methodes pour l'utilisation de 5'-adenosine diphosphate ribose (adpr) Active CA3014071C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662296665P 2016-02-18 2016-02-18
US62/296,665 2016-02-18
US201662428721P 2016-12-01 2016-12-01
US62/428,721 2016-12-01
PCT/US2017/018253 WO2017143113A1 (fr) 2016-02-18 2017-02-17 Méthodes pour l'utilisation de 5'-adénosine diphosphate ribose (adpr)

Publications (2)

Publication Number Publication Date
CA3014071A1 CA3014071A1 (fr) 2017-08-24
CA3014071C true CA3014071C (fr) 2026-03-03

Family

ID=

Similar Documents

Publication Publication Date Title
AU2023201678B2 (en) Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
CN105142637B (zh) 用于预防或治疗干眼症的含瑞巴派特或其前药的口服药物组合物
JP2024506384A (ja) ロフルミラストの眼科的送達方法
WO2025122455A1 (fr) Méthodes d'utilisation de la 5'-adénosine diphosphate ribose (adpr) pour la modulation du vegf
US10940144B2 (en) Drug containing pyridylaminoacetic acid compound
CA3014071C (fr) Methodes pour l'utilisation de 5'-adenosine diphosphate ribose (adpr)
TWI816660B (zh) 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途
HK40073052A (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
HK1263210B (en) Medical use of 5'-adenosine diphosphate ribose (adpr)
KR20150090045A (ko) 피나플록사신 현탁 조성물
CN104981243A (zh) 含有四氢吡喃基氨基环戊基羰基四氢吡啶并吡啶衍生物作为有效成分的眼后段疾病的预防或治疗剂
HK40016534A (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient